Development of antifungal biopharmaceutical dectin1-FC fusion
Invasive fungal infections are a neglected category of disease that has a high mortality and implicated in immunocompromised patients. Dectin-1 (CLEC7A) is a type II transmembrane C-type lectin pattern recognition receptor expressed on innate immune cells such as macrophages, monocytes and neutrophi...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Final Year Project |
| Language: | English |
| Published: |
2018
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10356/75181 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Nanyang Technological University |
| Language: | English |
| Summary: | Invasive fungal infections are a neglected category of disease that has a high mortality and implicated in immunocompromised patients. Dectin-1 (CLEC7A) is a type II transmembrane C-type lectin pattern recognition receptor expressed on innate immune cells such as macrophages, monocytes and neutrophils. These cells identify β-glucans via its single C-type lectin-like domain on its extracellular region. It activates by detecting and binding to cell walls of different types of fungal; triggering intracellular responses like phagocytosis and cytokine production. The absence of β-glucans in human cells presents the opportunity to exploit Dectin-1 as therapeutic vehicle to enhance immune response during a fungal infection. This project aims to develop a soluble Dectin-1 immunoglobulin Fc fragment fusion protein as a potential biopharmaceutical against fungal infections and investigate its ability to enhance phagocytic activity in immune cells. His-trap purification column will also be optimized in this project to obtain optimum purification conditions for this protein. |
|---|